Activities

Business model

Signed material transfer agreements (MTAs) with over 100 research institutions and universities.
Exploring new uses globally with the peptide platform technology.

Business model
In addition to surgical treatment, which is already being commercialized, we are also conducting R&D in the huge markets of regenerative medicine and DDS.

In addition to surgical treatment, which is already being commercialized, we are also conducting R&D in the huge markets of regenerative medicine and DDS.

Surgical Treatment

With a focus on Purestat, which has the strength not only in hemostasis but also in overall strength, we are developing postoperative bleeding materials, mucous membrane lifting-up solutions, vascular embolization materials and so on.

Regenerative Medicine

We are developing products for radiation proctitis (RP), inflammatory bowel disease (IBD), wound healing in the field of cosmetic surgery, and bone and heart muscle regeneration.

DDS

Based on the DDS technology to make the required drug act at the required site for the required length of time, we are promoting the delivery of nucleic acid drugs for cancer and malignant pleural mesothelioma.